Toggle navigation
About
Mission
Team
Our Science
Overview
HC-7366
HC-5404
Odetiglucan
Pipeline
Patients & Caregivers
News & Publications
Contact
Careers
About
Mission
Team
Our Science
Overview
HC-7366
HC-5404
Odetiglucan
Pipeline
Patients & Caregivers
News & Publications
Contact
Careers
News & Publications
News & Publications
News & Publications
All
News
Presentations &
Publications
By Topic
HiberCell's Publications
HC-5404 (PERK)
HC-7366 (GCN2)
Odetiglucan (dectin-1)
Overview
Clinical
Preclinical
All
News
Presentations &
Publications
By Topic
HiberCell's Publications
HC-5404 (PERK)
HC-7366 (GCN2)
Odetiglucan (dectin-1)
Overview
Clinical
Preclinical
All
--By Type--
News
Presentations & Publications
--By Topic--
HiberCell's Publications
HC-5404 (PERK)
Overview
HC-7366 (GCN2)
Clinical
Odetiglucan (dectin-1)
Preclinical
05.27.25 - news
HiberCell Announces Successful Completion of Dose Escalation and Enrollment Update for Ph1b Study Evaluating HC-7366 in Combination with WELIREG® (belzutifan) in Advanced ccRCC
Read More
04.28.25 - news
HiberCell’s Board of Directors Appoints Steven Gillis, Ph.D., the Company’s Current Chairman of the Board, as Chairman and Acting CEO
Read More
05.28.24 - news
HiberCell Announces First Patient Dosed in Phase 1b Clinical Trial, Evaluating HC-7366 in Combination with Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia (AML)
Read More
05.01.24 - news
HiberCell Announces First Patient Dosed in Clinical Collaboration with Merck, Evaluating HC-7366 in Combination with WELIREG® (belzutifan) in patients with advanced ccRCC
Read More
12.15.23 - publication
Activation of GCN2 By HC-7366 Results in Significant Anti-Tumor Efficacy As Monotherapy and Overcomes Resistance Mechanisms When Combined with Venetoclax in AML
Poster
Read More
12.05.23 - news
HiberCell, Inc. Announces Clinical Collaboration with Merck to Evaluate HC-7366, an Activator of ISR Kinase GCN2, in Combination with WELIREG® (belzutifan) in a Phase 1b Study of Patients with Clear Cell Renal Cell Carcinoma (ccRCC)
Read More
11.27.23 - news
HiberCell Announces Successful Completion and Interim Results of Phase 1 Study of Novel PERK Inhibitor, HC-5404, in Solid Tumors and Maps Forward Path as Monotherapy and in Combinations
Read More
10.10.23 - publication
Kupffer cells prevent pancreatic ductal adenocarcinoma metastasis to the liver in mice
Publication
Read More
09.19.23 - publication
PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors
Publication
Read More
09.01.23 - publication
A Phase 1b, Open-Label, 2-part, Safety, Tolerability, and Efficacy Study of a Soluble Beta-Glucan (Odetiglucan)
Poster
Read More
05.23.23 - news
HiberCell Announces FPD in Ph1b Combination in metastatic PDAC
Read More
04.19.23 - publication
Activation of GCN2 by HC-7366 results in significant antitumor efficacy as monotherapy
Poster
Read More
04.18.23 - publication
Inhibition of PERK by HC-5404 sensitizes clear cell renal cell carcinoma tumor models
Poster
Read More
04.17.23 - publication
Combination therapy using PERK and PD1/PD-L1 inhibitors reduces tumor burden
Poster
Read More
03.27.23 - news
HiberCell to Present Pre-clinical Data on its Novel GCN2 Activator and PERK Inhibitor Programs at the American Association for Cancer Research (AACR) Annual Meeting 2023
Read More
02.22.23 - news
HiberCell Maps Forward Path for Novel GCN2 Activator, HC-7366 in Acute Myeloid Leukemia (AML)
Read More
01.24.23 - publication
Activation of GCN2 by HC-7366 results in significant anti-tumor efficacy
Poster
Read More
11.30.22 - publication
Novel GCN2 Modulator HC-7366 Inhibits Myeloid-derived Suppressor Cells and Reduces Pulmonary Metastases
Poster
Read More
11.30.22 - publication
HC-5404 Demonstrates Immune-activation and Anti-tumor Efficacy
Poster
Read More
11.02.22 - news
HiberCell to Present Preclinical Data from Novel GCN2 Activator and PERK Inhibitor Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
Read More
10.28.22 - publication
Optimization of a Novel Mandelamide-Derived Pyrrolopyrimidine Series of PERK Inhibitors
Publication
Read More
10.26.22 - publication
Cancer immunotherapy via myeloid signaling pathway co-activation
Poster
Read More
05.26.22 - publication
Imprime PGG Enhances Anti-Tumor Effects of Tumor-Targeting, Anti-Angiogenic, and Immune Checkpoint Inhibitor Antibodies
Publication
Read More
05.24.22 - news
HiberCell to Present Posters on Novel Candidates Odetiglucan and HC-7366 at the 2022 Annual American Society of Clinical Oncology Meeting
Read More
05.13.22 - news
HiberCell and the University of Pennsylvania Present Preclinical Anti-Metastatic Monotherapy Activity Data in Mice for Odetiglucan in Pancreatic Cancer at AACR Annual Meeting 2022
Read More
04.28.22 - news
1st Patients Dosed in Phase 2 Clinical Trial of Odetiglucan in Combination with KEYTRUDA® in Adult Patients w/Metastatic, Hormone-Refractory Breast Cancer
Read More
03.09.22 - publication
Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer
Publication
Read More
03.03.22 - news
HiberCell to Present Clinical Applications of Odetiglucan and the Role of Beta-Glucan in Cancer Treatment
Read More
02.24.22 - news
HiberCell Initiates its Phase 1a/b Clinical Trial of HC-7366 in Patients with Advanced Solid Tumors
Read More
12.14.21 - news
HiberCell to Collaborate with Merck on Phase 2 Clinical Trial of Odetiglucan in Patients with Metastatic Breast Cancer
Read More
12.09.21 - news
HiberCell to Present Clinical Applications of Odetiglucan and the Role of Beta-Glucan in Cancer Treatment at ESMO Immuno-Oncology Virtual Congress 2021
Read More
12.07.21 - news
HiberCell To Present New Data on Odetiglucan Plus Pembrolizumab in Ongoing Phase 2 Metastatic Breast Cancer Trial at San Antonio Breast Cancer Symposium
Read More
09.30.21 - news
HiberCell Appoints Jonathan Lanfear as COO
Read More
09.24.21 - publication
Targeting the Integrated Stress Response in Cancer Therapy
Publication
Read More
09.08.21 - news
HiberCell Receives Fast Track Designation from FDA for First-in-Human Studies of PERK Inhibitor (PERKi) HC-5404-FU
Read More
08.16.21 - news
HiberCell Expands Translational Oncology Toolbox by Acquiring Genuity Science, Inc.
Read More
07.30.21 - publication
PERK inhibition blocks metastasis initiation by limiting UPR-dependent survival of dormant disseminated cancer cells
Publication
Read More
06.29.21 - news
HiberCell Appoints Mark J. Mulvihill, Ph.D., Chief Scientific Officer
Read More
06.10.21 - news
HiberCell Initiates Phase 1a Clinical Trial of HC-5404-FU, an ER Stress Modulator
Read More
05.19.21 - news
HiberCell Closes $67.4 Million Series B Financing and Secures $30 Million Debt Facility from Hercules Capital
Read More
02.21.21 - publication
Endoplasmic reticulum stress signals in the tumour and its microenvironment
Publication
Read More
01.21.21 - news
HiberCell Expands Scientific Advisory Board with Appointment of Lisa M. Coussens, Ph.D., and Ronald Wek, Ph.D.
Read More
01.13.21 - news
HiberCell and Biodesix Initiate Broad Collaboration forCompanion Diagnostic Discovery, Development and Commercialization
Read More
12.02.20 - news
HiberCell Bolsters Leadership Team with Appointment of Joseph Talamo as Chief Financial Officer and Promotion of Ari Nowacek, M.D., Ph.D., to Chief Business Officer
Read More
07.07.20 - news
HiberCell Announces Acquisition of Biothera Pharmaceuticals’ Imprime PGG Program
Read More
04.01.20 - publication
A novel, phase 2 study in second line +, metastatic triple negative breast cancer patients shows promising clinical benefit
Abstract
Read More
03.10.20 - publication
Immunoglobulin Restores Immune Responses to BTH1677 in Patients With Low Levels of Antibodies to Beta-glucan
Publication
Read More
12.04.19 - news
Nature Sponsored Feature – Pioneering the Discovery and Development of Novel Therapeutics to Prevent Metastasis
Read More
12.01.19 - publication
Response and clinical benefit assessment of the combination of the dectin-1 agonist Imprime PGG and anti-PD-1 pembrolizumab in chemotherapy-resistant metastatic triple negative breast cancer (TNBC)
Poster
Read More
11.01.19 - publication
Association of immunopharmacodynamic responses of Imprime PGG plus pembrolizumab with clinical benefit in metastatic triple negative breast cancer (TNBC) subjects
Poster
Read More
11.01.19 - publication
Clinical benefit evident with early immunopharmacodynamic responses in prior checkpoint failed metastatic melanoma patients treated with Imprime PGG and pembrolizumab
Poster
Read More
08.06.19 - news
HiberCell Strengthens Leadership Team with Appointment of Colin Goddard to Board of Directors
Read More
05.01.19 - publication
Immune Pharmacodynamic Responses of the Novel Cancer Immunotherapeutic Imprime PGG in Healthy Volunteers
Publication
Read More
02.07.19 - news
STAT – New York biotech debuts, targeting dormant metastatic cancer cells
Read More
02.07.19 - news
FierceBiotech – Biotech HiberCell launches with $60M+ to combat cancer relapse and metastasis
Read More
02.07.19 - news
Endpoints – Arch joins Celgene, China investors bankrolling a pioneering New York biotech startup focused on a new approach to metastasis
Read More
02.07.19 - news
HiberCell Launches to Prevent Cancer Relapse and Metastasis with Novel Therapeutics
Read More
10.16.18 - news
NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients
Read More
09.28.18 - news
How dormant cancer persists and reawakens
Read More
04.01.18 - publication
Imprime (β-1,3/1,6 glucan) synergizes with a CD40 agonist to stimulate T cell-dependent antitumor activity in a poorly immunogenic model of pancreatic carcinoma
Poster
Read More
04.01.18 - publication
Imprime PGG synergizes with anti-angiogenic antibodies to repolarize the immune microenvironment, suppressing xenograft tumor growth in vivo
Poster
Read More
04.01.18 - publication
Imprime PGG, a soluble yeast β-glucan PAMP, enhancement of anti-tumor responses in combination with tumor targeting antibody is highly dependent on NK cell killing
Poster
Read More
02.01.18 - publication
A randomized, controlled trial evaluating the efficacy and safety of BTH1677 in combination with bevacizumab, carboplatin, and paclitaxel in first-line treatment of advanced non-small cell lung cancer
Publication
Read More
12.13.16 - news
Mechanism of early dissemination and metastasis in Her2+ mammary cancer
Read More
11.01.16 - publication
Imprime PGG-Mediated Anti-Cancer Immune Activation Requires Immune Complex Formation
Publication
Read More
03.17.15 - publication
Early treatment of high risk chronic lymphocytic leukemia with alemtuzumab, rituximab and poly-(1-6)-beta-glucotriosyl-(1-3)- beta-glucopyranose beta-glucan is well tolerated and achieves high complete remission rates
Publication
Read More
01.30.15 - news
NR2F1 controls tumour cell dormancy via SOX9- and RARβ-driven quiescence programmes
Read More
08.01.13 - publication
Binding of soluble yeast β-glucan to human neutrophils and monocytes is complement-dependent
Publication
Read More
View More